THE LIBRARY: WEBINAR
Modernizing Pharmaceutical R&D with Metabolomics - Reducing Attrition with Better Models, Compounds, and Biomarkers
This webinar will convey the utility of metabolomics for developing or determining the most appropriate animal model for target/compound evaluation, providing a high-resolution assessment of compounds to add assurance and guidance in candidate selection, and elucidating sensitive and specific biomarkers of disease and response. Register today to tune into this live event.
Latest Commentary
EVENTS
- DIA 2013 49th Annual MeetingJune 23-27 — Boston, MA
- BioImmersion Three-Day CourseJuly 10-12 — Chicago, IL
- BioImmersion Three-Day CourseOctober 16-18 — Washington, D.C.
Press Releases
- New drug enhances radiation treatment for brain cancer in preclinical studies
- Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
- Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
- CardioDx Announces New Data Demonstrating Use of Corus® CAD in the Primary Care Setting for Evaluation of Symptomatic Patients with Suspected CAD Influences Clinical Decision Making
- Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B
- More Press Releases
Featured Jobs
-
Sr. Validation Scientist (Tech Services) Job
Celgene Corporation - Phoenix AZ US -
Clinical Trial Manager
Tesaro - Boston, MA -
Medical Director, UK and Ireland Job
Celgene Corporation - US -
Sr. Manager, Market Access Marketing
Regeneron Pharmaceuticals - Tarrytown NY -
Principal Scientist - Biochemistry
Syros Pharmaceuticals -
Let's not hold our breath for a device tax repeal
All the bipartisan agreement on repealing the medical device tax would suggest a short life for the 2.3% charge, but that's not quite how Washington works. Read more >>
GE Healthcare's Pascale Witz seeks better climate for Dx industry growth
Pascale Witz, GE Healthcare's president and CEO of medical diagnostics, was one of the thousands of life sciences executives at the BIO 2013 International Convention in Chicago this week, and she was in full-scale networking mode.
Third Rock remains undaunted by early-stage med tech investing
Venture capitalists have been focusing more on companies that are close to commercialization. But even as the venture capital industry has shifted its priorities to safer bets, VCs like Bob Tepper continue to keep early-stage investment prospects very much in mind.
Renal denervation: Medtronic, St. Jude vie for lion's share of billions
Cross-town rivals Medtronic and St. Jude Medical are leading the way in getting renal denervation technologies on the U.S. market, and while Medtronic has a definite head start, St. Jude believes it has the know-how to move quickly and capitalize on a market that could be worth close to $3 billion within a decade. Read more >>
In the wake of BrainGate, Brown U. debuts wireless brain sensor
Brain-computer interfaces at Brown University have taken another step forward. And the key this time is to go wireless and rechargeable. Brown sees the advance as a next-generation tool to help paralyzed patients move objects with their thoughts, minus being tethered to any connecting wires. Read more >>
For TearScience, royalty financing offered a new investor option
February ended with big funding news in the med tech world: HealthCare Royalty Partners' commitment of up to $70 million in debt financing to TearScience, the North Carolina maker of a dry eye treatment device and system. But the type of financing the company secured--royalty funding--is just as noteworthy. Read more >>
The Fierce barometer at J.P. Morgan
Another J.P. Morgan Healthcare Conference has come to a close. Be sure to check out our expansive conference slideshow, and, in case you missed any of our coverage, here's a rundown of Fierce's trip through J.P. Morgan >>
This time, 'cautious optimism' at the J.P. Morgan Healthcare Conference
Broadly speaking, as far down as the device industry tumbled with the economic crash a few years back, folks are starting to see brief bits of sunshine and are hoping for more.
JP Morgan 2013 is almost upon us
Just a quick note to tell you that by this time on Monday, we'll be in San Francisco gearing up for some major coverage of JP Morgan 2013.
Here's what you missed during the holiday break
Welcome back after a nice holiday breather, and Happy New Year to all. While many were on holiday break this last week or so, the device and diagnostics industries were anything but quiet.